Sight Sciences Inc (SGHT) FinancialsSGHTSight Sciences Inc

Sight Sciences, Inc. (SGHT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Surgical Glaucoma, accounting for 88.6% of total sales, equivalent to $20.71M. Another important revenue stream is Dry Eye. Understanding this composition is critical for investors evaluating how SGHT navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Sight Sciences, Inc. maintains a gross margin of 90.96%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -17.05%, while the net margin is -19.01%. These profitability ratios, combined with a Return on Equity (ROE) of -48.42%, provide a clear picture of how effectively SGHT converts its operational activities into shareholder value.

In the context of the broader market, SGHT competes directly with industry leaders such as NNNN and ANGO. With a market capitalization of $484.77M, it holds a significant position in the sector. When comparing efficiency, SGHT's gross margin of 90.96% stands against NNNN's 87.24% and ANGO's 56.00%. Such benchmarking helps identify whether Sight Sciences, Inc. is trading at a premium or discount relative to its financial performance.

Sight Sciences has shown a gross margin of 90.96% in Q2 2026, indicating strong profitability on sales, but it continues to report net losses, with a net income of -4.446 million USD in the same quarter. The company has a current ratio of 4.95, suggesting good short-term liquidity, but its debt to equity ratio is rising at 77.09%.